Kabra Drugs Ltd
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.[1]
- Market Cap ₹ 53.3 Cr.
- Current Price ₹ 22.5
- High / Low ₹ 35.5 / 12.2
- Stock P/E 10.8
- Book Value ₹ 12.5
- Dividend Yield 0.00 %
- ROCE 20.8 %
- ROE 18.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has a low return on equity of 7.79% over last 3 years.
- Company has high debtors of 279 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.24 | 9.59 | 7.61 | 1.81 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 92.74 | |
| 7.77 | 9.14 | 7.17 | 2.84 | 0.09 | 0.05 | 0.15 | 0.18 | 0.35 | 0.74 | 1.72 | 87.41 | |
| Operating Profit | 0.47 | 0.45 | 0.44 | -1.03 | -0.13 | -0.05 | -0.15 | -0.18 | -0.35 | -0.74 | -1.72 | 5.33 |
| OPM % | 5.70% | 4.69% | 5.78% | -56.91% | -150.00% | -3,400.00% | 5.75% | |||||
| 0.01 | 0.02 | 0.11 | -0.94 | 0.01 | 0.02 | 0.00 | 0.00 | 0.01 | 0.00 | 0.64 | 0.49 | |
| Interest | 0.14 | 0.18 | 0.17 | 0.25 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Depreciation | 0.23 | 0.24 | 0.24 | 0.14 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.01 | 0.07 |
| Profit before tax | 0.11 | 0.05 | 0.14 | -2.36 | -0.16 | -0.06 | -0.18 | -0.19 | -0.34 | -0.74 | -1.09 | 5.72 |
| Tax % | 36.36% | 40.00% | 7.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 13.46% |
| 0.07 | 0.03 | 0.13 | -2.36 | -0.16 | -0.06 | -0.18 | -0.19 | -0.34 | -0.74 | -1.09 | 4.96 | |
| EPS in Rs | 0.16 | 0.07 | 0.30 | -5.38 | -0.36 | -0.14 | -0.41 | -0.43 | -0.77 | -1.69 | -0.46 | 2.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 97% |
| 3 Years: | 155% |
| TTM: | 555% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 35% |
| 3 Years: | 61% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 18% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 4.39 | 23.71 | 23.71 |
| Reserves | -1.78 | -1.76 | -1.84 | -4.19 | -4.36 | -4.42 | -4.60 | -4.78 | -5.12 | -3.31 | 0.95 | 5.91 |
| 2.81 | 2.39 | 1.80 | 0.70 | 0.67 | 0.65 | 0.90 | 1.03 | 1.38 | 1.71 | 0.44 | 0.57 | |
| 3.12 | 4.15 | 2.03 | 0.80 | 0.78 | 0.79 | 0.71 | 0.09 | 0.05 | 1.78 | 0.13 | 56.08 | |
| Total Liabilities | 8.54 | 9.17 | 6.38 | 1.70 | 1.48 | 1.41 | 1.40 | 0.73 | 0.70 | 4.57 | 25.23 | 86.27 |
| 2.78 | 2.73 | 2.48 | 0.11 | 0.08 | 0.04 | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.84 | |
| CWIP | 0.10 | 0.21 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5.66 | 6.23 | 3.69 | 1.59 | 1.40 | 1.37 | 1.39 | 0.73 | 0.70 | 4.57 | 25.19 | 85.43 | |
| Total Assets | 8.54 | 9.17 | 6.38 | 1.70 | 1.48 | 1.41 | 1.40 | 0.73 | 0.70 | 4.57 | 25.23 | 86.27 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.22 | 0.28 | 0.31 | -0.12 | -0.18 | -0.05 | -0.25 | -0.13 | -0.35 | -0.21 | -4.71 | -9.47 | |
| -0.20 | -0.29 | 0.01 | 1.50 | 0.07 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -1.36 | |
| 0.58 | -0.27 | -0.32 | -1.35 | 0.00 | -0.02 | 0.25 | 0.13 | 0.36 | 2.88 | 23.39 | 0.12 | |
| Net Cash Flow | 0.16 | -0.28 | 0.00 | 0.04 | -0.10 | 0.00 | 0.00 | -0.01 | 0.00 | 2.67 | 18.63 | -10.72 |
| Free Cash Flow | -0.43 | -0.03 | 0.31 | 1.38 | -0.18 | -0.04 | -0.25 | -0.13 | -0.35 | -0.21 | -4.76 | -10.17 |
| CFO/OP | -38% | 67% | 73% | 10% | 138% | 100% | 167% | 72% | 100% | 28% | 274% | -173% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 198.00 | 204.00 | 141.49 | 254.09 | -11,406.25 | 278.57 | ||||||
| Inventory Days | 25.58 | 16.04 | 16.73 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | 129.78 | 139.88 | 97.33 | |||||||||
| Cash Conversion Cycle | 93.81 | 80.16 | 60.89 | 254.09 | -11,406.25 | 278.57 | ||||||
| Working Capital Days | 85.93 | 69.65 | 34.05 | -28.23 | -912.50 | 66.12 | ||||||
| ROCE % | 4.40% | 4.41% | 6.62% | -44.19% | -18.75% | -9.09% | -27.48% | -28.57% | -52.71% | -43.02% | -7.82% | 20.80% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Packing Material Consumed INR |
|
|||||||||||
| Operating Status (1 = Operational, 0 = Non-Operational) Binary |
||||||||||||
| Total Raw Material Consumption (Combined) INR |
||||||||||||
| Raw Material Consumption - RM 1 (K.G.) INR |
||||||||||||
| Raw Material Consumption - RM 2 (Litre) INR |
||||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Jun
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 May - Kabra Drugs reported FY26 audited income of ₹93.23 crore, PAT ₹4.96 crore; outlines pharma and AI-defence expansion.
-
Undertaking For Non- Applicability Of Regulation 32 Of SEBI (LODR) Regulations 2015 For The Quarter Ended On 31St March 2026.
29 May - 29 May 2026 undertaking filed: Regulation 32 not applicable, as no public, rights or preferential issue occurred.
-
Financial Results For Quarterly & Year Ended 31St March 2026.
29 May - Audited Q4/FY26 results approved; FY26 revenue Rs 9,274 lakh, net profit Rs 495.98 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May 2026
29 May - Board approved audited FY26 results; PAT rose to Rs 495.98 lakh, with unmodified audit opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
KDL is in the business of manufacturing Perma
culture and trading in the pharma-related product.